Agitation associated with Alzheimer disease carries clinical challenges, and Auvelity's approval can reshape treatment selection, safety monitoring, and the pharmacist's role.

Erica Marini, PharmD, and Millad Sobhanian, PharmD, BCPS, unpack Auvelity's approval, efficacy data, and safety profile for treating agitation in Alzheimer disease.

Tim Pflederer, MD, of Evergreen Nephrology explains why proteinuria, diabetes, and heart failure all point toward the same two drug classes.

Food as Medicine programs that do not include pharmacist-led food-drug interaction screening are clinically incomplete.

Hackensack Meridian Health uses a multifaceted approach to diversion auditing and DEA/state reporting requirements, and is beginning to integrate artificial Intelligence (AI) to shift surveillance from a reactive to a proactive process.

Taking a new medication is a step toward healing, but danger may lie in how different drugs, supplements, and even foods and drinks react behind the scenes.